Apo Hydromorphone 1mg Tablets Canada

Description

### APO-HYDROMORPHONE 1MG TABLETS CANADA

### UNDERSTANDING HYDROMORPHONE HYDROCHLORIDE IN APO-HYDROMORPHONE 1MG TABLETS CANADA

Hydromorphone hydrochloride is a potent semi-synthetic opioid agonist derived from morphine. It primarily binds to mu-opioid receptors in the central nervous system, altering the perception of and emotional response to pain. In the immediate-release formulation of Apo-Hydromorphone 1mg Tablets Canada, effects typically begin within 30 minutes, with a duration of action of about 4 to 5 hours. This makes it suitable for managing breakthrough pain or acute moderate to severe pain episodes under medical supervision.

Health Canada approves hydromorphone exclusively for adults when non-opioid analgesics (such as acetaminophen or NSAIDs) or weaker opioids do not provide sufficient relief. Canadian prescribers align use with the *2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain* (and any subsequent updates), which stresses optimizing non-opioid and non-pharmacologic therapies first, shared decision-making, and careful risk-benefit assessment.

### INDICATIONS FOR USE OF APO-HYDROMORPHONE 1MG TABLETS IN CANADIAN PRACTICE

Apo-Hydromorphone 1mg Tablets Canada is indicated for the relief of moderate to severe pain in adults. In Canadian healthcare settings, it may be prescribed in contexts such as:

* Post-operative pain management following surgery in hospitals across all provinces.
* Severe acute pain from trauma, kidney stones, pancreatitis, or other conditions treated in emergency departments nationwide.
* Cancer-related pain or palliative care under the supervision of specialists through provincial cancer agencies or palliative programs.
* Short-term management of severe pain flares when other treatments are ineffective or not tolerated.

The 1 mg strength is typically used as a starting dose for opioid-naïve patients, elderly patients, or those requiring careful initial titration under close supervision. This medication is intended for chronic pain management when other treatments like morphine are unsuccessful or cause intolerable side effects .

Health Canada has not authorized its use in pediatrics . In geriatric patients, initiation requires lower starting doses with slow titration due to increased sensitivity to opioid effects. Use is contraindicated during pregnancy, labour, delivery, or breastfeeding due to the risk of neonatal opioid withdrawal syndrome .

### CONTRAINDICATIONS FOR APO-HYDROMORPHONE 1MG TABLETS CANADA

Strict contraindications exist to protect patient safety:

* Hypersensitivity to hydromorphone, other opioids, or any ingredient in the formulation.
* Known or suspected mechanical gastrointestinal obstruction, paralytic ileus, or suspected surgical abdomen (e.g., acute appendicitis or pancreatitis) .
* Acute or severe bronchial asthma, chronic obstructive airway, status asthmaticus, or significant respiratory depression.
* Acute alcoholism, delirium tremens, or convulsive disorders.
* Severe central nervous system depression, head injury with increased intracranial pressure (risk of increased intracranial pressure and respiratory depression) .
* Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs).
* Mild pain that can be adequately managed with non-opioid therapies.

### SERIOUS WARNINGS AND PRECAUTIONS FOR APO-HYDROMORPHONE 1MG TABLETS

Health Canada’s product monograph highlights serious warnings, including:

* **Addiction, Abuse, and Misuse:** Potential exists even at recommended doses. Risk assessment tools and ongoing monitoring are required in line with Canadian guidelines. Misuse is usually not a problem when used appropriately for pain relief .
* **Life-Threatening Respiratory Depression:** Hydromorphone can cause serious breathing problems . Risk is highest during initiation or dose escalation, particularly in elderly patients or those with respiratory conditions such as sleep apnea or chronic lung conditions (bronchitis, emphysema, asthma) .
* **Accidental Exposure:** Accidental ingestion or use of as little as one dose by someone for whom it has not been prescribed can lead to a fatal overdose. Children are especially at risk. Secure storage in child-resistant packaging is mandatory .
* **Neonatal Opioid Withdrawal Syndrome:** Prolonged use in pregnancy can lead to severe withdrawal in newborns. Infants born to mothers physically dependent on hydromorphone will also be physically dependent and may experience breathing difficulties and withdrawal symptoms .
* **Interactions with Alcohol and CNS Depressants:** Combining with alcohol, benzodiazepines, sleeping pills, anxiety medications, antidepressants, or other sedatives greatly increases the risk of additive drowsiness and reduced breathing, which can be dangerous and possibly life-threatening .
* **Administration Instructions:** Swallow tablets whole with water. Do not crush, chew, break, or dissolve, as this can cause rapid release and serious harm.
* **Dependence and Withdrawal:** As with other opioid medications, this medication may become habit-forming if taken for long periods. Withdrawal symptoms (body aches, diarrhea, nausea, nervousness, restlessness, goose bumps, shaking, stomach cramps, fast heart rate, fever, sweating) may occur if stopped suddenly. Reducing the dose gradually under medical supervision can help prevent or decrease these symptoms .

Canadian patients are encouraged to access take-home naloxone through provincial harm reduction programs.

### DOSAGE AND ADMINISTRATION OF APO-HYDROMORPHONE 1MG TABLETS CANADA

Dosing is highly individualized based on pain severity, prior opioid exposure, age, weight, and organ function. The 1 mg tablet is typically used as a starting dose for patients who are opioid-naïve, elderly, or require careful titration. For patients with decreased kidney or liver function, the medication may build up in the body, requiring dose adjustment .

Take orally every 4 to 6 hours with a full glass of water. For acute pain, Health Canada recommends limiting use to a maximum of 7 days at the lowest effective dose. In chronic non-cancer pain, guidelines advise against exceeding 90 morphine milligram equivalents daily without thorough reassessment.

Adjustments are needed for hepatic or renal impairment (reduce dose), elderly patients (start low and go slow), and opioid rotation (reduce calculated equianalgesic dose due to incomplete cross-tolerance). Prescriptions for narcotics are often quantity- and duration-limited, with monitoring via provincial drug monitoring programs.

### COMMON AND SERIOUS SIDE EFFECTS OF APO-HYDROMORPHONE 1MG TABLETS

Very common side effects include constipation, nausea, vomiting, drowsiness, dizziness, and sedation. Constipation happens frequently while taking opioid pain relievers on a regular basis; ask your doctor or pharmacist for advice on how to manage it . Other frequent effects may include headache, dry mouth, itching, sweating, and fatigue.

Serious reactions that require immediate medical attention or reporting to Health Canada’s Canada Vigilance Program include:

* Respiratory depression (slowed breathing or difficulty breathing) .
* Severe low blood pressure (severe dizziness, especially when standing from a lying or sitting position) .
* Serotonin syndrome: a rare but potentially life-threatening condition with symptoms including muscle rigidity and spasms, difficulty moving, changes in mental state including delirium and agitation. Coma and death are possible. Risk increases if taking certain antidepressants (tricyclic antidepressants, serotonin reuptake inhibitors) .
* Adrenal insufficiency.
* Opioid-induced hyperalgesia (paradoxical increase in pain).
* Allergic reactions or seizures (may occur with substantial dose increases above recommended levels) .
* Worsening of pre-existing seizure disorders .

Patients should promptly report any concerning symptoms to their healthcare team.

### DRUG INTERACTIONS WITH APO-HYDROMORPHONE 1MG TABLETS CANADA

Significant interactions can occur with:

* **Alcohol** – Do not drink alcohol while taking this medication. It can lead to unusually slow or weak breathing, serious side effects, or fatal overdose .
* **Other central nervous system depressants** – Benzodiazepines, sleeping pills, anxiety medications, antidepressants, sedatives, muscle relaxants, and antihistamines can cause additive drowsiness and reduced breathing which can be life-threatening .
* **Serotonergic medications** – Certain antidepressants (tricyclic antidepressants, serotonin reuptake inhibitors, MAOIs) and migraine treatments increase risk of serotonin syndrome .
* **Monoamine oxidase inhibitors** – Do not take with MAO inhibitors or if you have taken them in the last 14 days.
* **Anticholinergic drugs** – Increased risk of severe constipation or urinary retention.
* **Other medical conditions** – Hydromorphone may worsen symptoms for people with Addison’s disease, enlarged prostate (BPH), hypothyroidism, irregular heart rhythms, or narrowing of the urethra .

Canadian pharmacists routinely screen for interactions using provincial drug information systems. Patients must disclose all medications and substances they use.

### BUY APO-HYDROMORPHONE NEAR ME IN CANADA

This medication is available only with a valid prescription from a licensed Canadian healthcare provider. It can be dispensed at any licensed pharmacy, including national chains and independent community pharmacies across all provinces and territories.

Provincial drug benefit plans may offer coverage under specific criteria. In Quebec, for example, Apo-Hydromorphone 1mg is listed on the RAMQ formulary for chronic pain treatment when other opioids have failed or caused intolerable side effects . When travelling within Canada or internationally, patients must comply with federal regulations for controlled substances.

### CANADA’S OPIOID CRISIS AND RESPONSIBLE APO-HYDROMORPHONE USE

Canada has experienced significant opioid-related harms. While some regions have seen declines due to harm reduction efforts, vigilance remains critical.

The *2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain* promotes: prioritizing non-opioid therapies; using the lowest effective dose for the shortest duration; regular monitoring; and providing access to take-home naloxone.

### COMPARISON WITH OTHER OPIOIDS AVAILABLE IN CANADA

Hydromorphone is approximately five times more potent than oral morphine on a milligram-to-milligram basis. Apo-Hydromorphone 1mg is the lowest available strength in the Apo-Hydromorphone product line and is suitable for opioid-naïve patients requiring a gentle starting dose . Canadian prescribers choose between generics of hydromorphone, morphine, oxycodone, or codeine based on patient-specific factors and provincial formularies.

### PATIENT MEDICATION INFORMATION FOR APO-HYDROMORPHONE 1MG TABLETS

Read the patient information leaflet supplied with your prescription. Key instructions include:

* Take exactly as directed by your healthcare professional.
* Swallow tablets whole; do not alter them.
* Do not share or sell the medication.
* Avoid driving or operating machinery until you understand how it affects you .
* Report any side effects promptly.
* Manage constipation by drinking plenty of water and eating more dietary fibre .

### STORAGE, HANDLING, AND DISPOSAL OF APO-HYDROMORPHONE 1MG TABLETS CANADA

Store tablets at room temperature, protected from light, in the original child-resistant packaging. Keep locked away and out of sight/reach of children and pets. Dispose of unused or expired tablets through pharmacy take-back programs or authorized collection sites.

### FREQUENTLY ASKED QUESTIONS ABOUT APO-HYDROMORPHONE 1MG TABLETS CANADA

**Can I drive while taking Apo-Hydromorphone 1mg Tablets Canada?** It is not recommended until you know how the medication affects your alertness and coordination, as it can cause significant drowsiness and impair judgment. Do not drive or operate dangerous machinery unless you have determined that the medication does not affect your ability to do so .

**What should I do if I miss a dose?** Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Do not double the dose. Consult your pharmacist or doctor for guidance.

**Has Apo-Hydromorphone 1mg experienced supply shortages?** Yes, there have been previous supply disruptions. A shortage was reported in August 2017 due to a disruption of manufacture, resolved by August 31, 2017 . Another shortage was reported from October 24, 2023, resolved by December 14, 2023 . Contact your pharmacy for current availability.

### HISTORY AND MANUFACTURING OF APO-HYDROMORPHONE BY APOTEX IN CANADA

Apotex Inc. has been a trusted supplier of high-quality generic medications to Canadians for decades. The company’s production of Apo-Hydromorphone supports affordable access while adhering to Health Canada’s rigorous manufacturing and quality standards. Apo-Hydromorphone 1mg has been marketed in Canada since December 18, 2012 .

### THE CANADIAN REGULATORY FRAMEWORK FOR APO-HYDROMORPHONE 1MG TABLETS

This product is regulated under the *Controlled Drugs and Substances Act* (CDSA) as a narcotic (CDSA I), the *Narcotic Control Regulations*, and the *Food and Drugs Act* . A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) has been submitted for this product, which includes Healthcare Professional Education materials and Observational Studies . Prescribing, dispensing, record-keeping, and monitoring follow both federal and provincial requirements.

### PROVINCIAL AND TERRITORIAL VARIATIONS IN ACCESS AND MONITORING

Access, coverage, prescription monitoring programs, and harm reduction services differ across provinces and territories (for example, risk mitigation guidance in British Columbia, narcotics monitoring in Ontario, and services through RAMQ in Quebec).

### EVIDENCE BASE AND CANADIAN RESEARCH ON OPIOID USE FOR PAIN

Canadian studies and guideline development processes inform the safe and effective use of opioids like hydromorphone, with emphasis on balancing pain relief and harm reduction.

### SUPPORT RESOURCES FOR CANADIAN PATIENTS AND CAREGIVERS

* Provincial pain clinics and palliative care services.
* Addiction and mental health support programs.
* Public naloxone distribution initiatives.
* Health Canada and provincial ministry resources for safe medication use.
* Health Canada’s Canada Vigilance Program for reporting side effects .

—

**DISCLAIMER:** This article is for informational and educational purposes only and is not medical advice. Hydromorphone is a potent Schedule I controlled narcotic available in Canada only by prescription. All use must be supervised by a licensed Canadian healthcare professional. Misuse or improper use can cause addiction, life-threatening respiratory depression, overdose, and death. In an emergency, call 911 or your provincial poison control centre immediately. Always verify the latest information on the Health Canada Drug Product Database and consult your healthcare team for personalized advice.

### CONCLUSION: RESPONSIBLE USE OF APO-HYDROMORPHONE 1MG TABLETS IN CANADA

When prescribed and used appropriately under medical supervision in accordance with Health Canada standards and Canadian guidelines, Apo-Hydromorphone 1mg Tablets can provide important relief for moderate to severe pain, particularly for patients requiring a low starting dose. Patient safety, informed consent, adherence to directions, and collaboration with your healthcare team are essential. Prioritize non-opioid options whenever possible and utilize available support resources.

**DISCLAIMER:** This article is for informational and educational purposes only and does not constitute medical advice. Apo-Hydromorphone 1mg tablets is a prescription-only Schedule I controlled narcotic under the *Controlled Drugs and Substances Act* in Canada, manufactured by Apotex Inc. It is authorized by Health Canada for the relief of moderate to severe pain in adults when non-opioid alternatives are inadequate. Always consult your licensed Canadian healthcare professional before starting, adjusting, or stopping this medication. Individual responses vary. Always verify the most current product information on the Health Canada Drug Product Database.

—

**Apo-Hydromorphone 1mg Tablets Canada** is an immediate-release opioid analgesic produced by Apotex Inc., a major Canadian pharmaceutical company based in Toronto, Ontario . Marketed since December 18, 2012, this product meets stringent Health Canada standards for quality, safety, and efficacy . The 1 mg strength tablet contains 1 mg of hydromorphone hydrochloride as the active ingredient (DIN: 02364115) and is available in bottles of 100 tablets . A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) has been submitted for this product, which includes Healthcare Professional Education materials and Observational Studies .